食道癌における高発現遺伝子抑制:創薬ターゲット遺伝子の同定

食管癌高表达基因的抑制：药物靶基因的鉴定

• 批准号: 18790970
• 负责人: 石黒 秀行
• 金额: $ 2.24万
• 依托单位: Nagoya City University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Young Scientists (B)
• 财政年份: 2006
• 资助国家: 日本
• 起止时间: 2006 至 2007
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-18790970/
• 关键词: マイクロアレイ; 食道癌; Caveolin; caveolin2

前年度までに解析した遺伝子のうち,細胞株での再現性を確認したところ,正常細胞株HET1Aと比較して,すべての食道癌癌細胞株での発現上昇が認められたCaveolin2に関して解析を進めた。Caveolin1とcaveolin2はcaveolaeの主要な構成タンパクである。TE1-15の食道癌細胞株で,CAV1もCAV2も高発現を認めていた。臨床検体47例に関して,RTPCRによる発現定量と抗体を用いた免疫染色を施行した。RTPCRの解析では,癌部での発現は,非癌部の発現と比較して有意に高発現であった。(CAV1,p=0.0024,CAV2,p=0.0136)その他の臨床病理学的因子とは相関は認めなかった。免疫組織染色では,CAV1は,13/47(27.7%)で陽性であり,CAV2は22/47(46.8%)に陽性であった。CAV1とCAV2の免疫染色とT因子,Ly因子,V因子,分化度に重要な相関を認めた。CAV1がpositive症例はnegativeな症例より生存期間が短い傾向にあった。CAV2がpositive症例についてもnegativeな症例より生存期間が短い傾向にあった。これらの結果はCAV1とCAV2が重要な予後因子であり,食道癌治療のターゲットとなりうることを示唆していた。さらにCAV1のRNAiを用い,食道癌細胞株におけるCAV1の発現を抑制し,治療に応用を目指したが,現在までにpositiveなdataは得られていない。今後さらに解析をすすめる予定である。

In the previous year, the results showed that the cell lines were confirmed to be sensitive, the normal cell lines were HET1A positive, and the esophageal cancer cell lines were significantly higher than those of esophageal cancer cell lines. The results showed that there was a significant improvement in Caveolin2 gene analysis. The Caveolin1 "caveolin2" caveolae is mainly used as a tool. TE1-15 esophageal cancer cell line, CAV1 CAV2 cell line. In 47 patients, the RTPCR antibody was detected by immunostaining. RTPCR analysis showed that the incidence of cancer was higher than that of non-cancer, while that of non-cancer was higher than that of cancer. (CAV1,p=0.0024,CAV2,p=0.0136) the factors of bed pathology are related to each other. Immunocytochemical staining showed that CAV1 staining was positive, 13max 47 (27.7%) was positive, CAV2 22 was 47 (46.8%). CAV1 "CAV2" immunostaining showed T factor, Ly factor, V factor, and the degree of differentiation was important. Cases of CAV1's positive's disease and cases of negative's disease had a short period of survival. The cases of CAV2's positive, the cases of negative's, the cases of negative's disease, the cases of SARS, and the cases of SARS. The results showed that CAV1 CAV2 was an important predictor of esophageal cancer, and the treatment of esophageal cancer. CAV1 RNAi was used, esophageal cancer cell line CAV1 was suppressed, and eye finger was used to treat esophageal cancer. Now, esophageal cancer cell line positive data has been successfully treated. In the future, we will analyze the predetermined conditions.